China Academy of Chinese Medical Sciences, Xiyuan Hospital, Beijing, PR China.
J Ethnopharmacol. 2010 Oct 5;131(3):562-6. doi: 10.1016/j.jep.2010.07.040. Epub 2010 Jul 24.
Salvia miltiorrhiza (SM, also known as DanShen) is one of the well-known widely-used Chinese herbal medicines in clinical practice. In this study we aimed to demonstrate the pro-angiogenic effects of Salvianolic acids (SAs) to treat illnesses such as ischemic cardiovascular diseases, the main active components of aqueous extract of SM.
To do this, new-born rat spleen mononuclear cells were isolated and endothelial progenitor cells (EPCs) were expanded (not more than 24h) SD. Then the pro-angiogenic activities of SAs were evaluated on in vitro cultured EPCs and chick embryo chorioallantoic membrane (CAM) model. And the adherent cells were stained with DiI complexed acetylated low-density lipoprotein (DiI-acLDL) and fluorescein Ulex Europaeus agglutinin-1 (FITC-UEA-1), and then viewed by laser scanning confocal microscope (LSCM) to confirm EPCs lineage. EPCs identification was also tested by ultrastructural analyses. EPCs proliferation, migration and in vitro vasculogenesis activity were assayed with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, transwell chamber assay and in vitro vasculogenesis kit, respectively. EPCs adhesion assay was performed by replating those on fibronectin-coated dishes, and then counting adherent cells.
EPCs phenotype was confirmed by the presence of double positive cells for DiI-acLDL uptake and lectin binding and identification of Weibel-Palade body in cytoplasm by ultrastructural analyses. Incubation of EPCs with SAs increased the number of EPCs and promoted EPCs migratory, adhesive and in vitro vasculogenesis capacity. SAs also promoted angiogenesis as evidenced by CAM model.
The results of the present study suggest that SAs may have utility for therapeutic postnatal vasculogenesis of ischemic tissue, contributing to the clinical benefit of SM therapy in patients with coronary artery disease.
丹参(SM,又称 DanShen)是临床实践中广泛使用的中药之一。本研究旨在证明丹酚酸(SAs)具有促血管生成作用,可治疗缺血性心血管疾病等疾病,这是 SM 水提物的主要活性成分。
为此,分离新生大鼠脾单核细胞并扩增内皮祖细胞(EPCs)(不超过 24 小时)。然后,在体外培养的 EPC 和鸡胚绒毛尿囊膜(CAM)模型上评估 SAs 的促血管生成活性。用 DiI 复合物乙酰化低密度脂蛋白(DiI-acLDL)和荧光标记的荆豆凝集素-1(FITC-UEA-1)染色贴壁细胞,然后通过激光扫描共聚焦显微镜(LSCM)观察,以确认 EPC 谱系。还通过超微结构分析测试 EPCs 的鉴定。通过 3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐(MTT)测定、Transwell 室测定和体外血管生成试剂盒分别测定 EPCs 增殖、迁移和体外血管生成活性。通过将细胞重新接种到纤维连接蛋白包被的培养皿中进行 EPC 黏附测定,然后计数黏附细胞。
通过 DiI-acLDL 摄取和凝集素结合的双阳性细胞以及超微结构分析中细胞质中 Weibel-Palade 体的鉴定,确认了 EPCs 表型。SAs 孵育 EPCs 增加了 EPCs 的数量,并促进了 EPCs 的迁移、黏附和体外血管生成能力。CAM 模型也证明 SAs 促进了血管生成。
本研究结果表明,SAs 可能对缺血组织的治疗性出生后血管生成具有实用价值,有助于 SM 治疗冠心病患者的临床获益。